Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPS1 | P31327 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 4/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.42 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29951438 | 0.98 | CPS1 (0.52) | CPS1HPGDUSP2LMNACNR1 | |
| SCHEMBL29952444 | 0.88 | TSHR (0.55) | CPS1HPGDUSP2LMNACNR1 | |
| SCHEMBL951604 | 0.87 | MAPT (0.55) | CPS1CNR1TSHRKDM4EMEN1 | |
| SCHEMBL29951371 | 0.86 | TSHR (0.57) | CPS1HPGDUSP2LMNACNR1 | |
| SCHEMBL9886019 | 0.85 | CPS1 (0.46) | CPS1HPGDTSHRKDM4EMEN1 | |
| SCHEMBL29955460 | 0.81 | HPGD (0.53) | HPGDUSP2LMNATSHRMEN1 | |
| SCHEMBL951383 | 0.80 | CNR1 (0.42) | CPS1HPGDCNR1KDM4EKCNH2 | |
| SCHEMBL17404610 | 0.80 | CPS1 (0.50) | CPS1LMNAMEN1KMT2A | |
| SCHEMBL29952513 | 0.80 | HPGD (0.55) | HPGDUSP2LMNATSHRMEN1 | |
| SCHEMBL29816274 | 0.79 | CNR1 (0.63) | CPS1HPGDUSP2CNR1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-9359311-B2 | Substituted aromatic oligomers | NEUROSCIOS GMBH (AT) | 2016-06-07 | — | — | US | disclosed |
| EP-2817304-A1 | NOVEL COMPOUNDS AND THEIR USE IN THERAPY | BioChromix NewCo AB (SE) | 2014-12-31 | — | — | EP | disclosed |
| US-20140135322-A1 | NOVEL COMPOUNDS AND THEIR USE IN THERAPY | BIOCHROMIX PHARMA AB | 2014-05-15 | — | — | US | disclosed |
| WO-2013036196-A1 | NOVEL THIOPHENE COMPOUNDS AND METHOD FOR IN VIVO IMAGING | BIOCHROMIX AB (SE) | 2013-03-14 | — | — | WO | disclosed |
| WO-2013009259-A1 | NOVEL COMPOUNDS AND THEIR USE IN THERAPY | BIOCHROMIX PHARMA AB (SE) | 2013-01-17 | — | — | WO | disclosed |
| US-8034940-B2 | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-11 | — | — | US | disclosed |
| US-8034940-B2 | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-11 | — | — | US | disclosed |
| US-8034940-B2 | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-11 | — | — | US | disclosed |
| EP-2049507-A2 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AND/OR AP-1, AND/OR NF-KB ACTIVITY AND USE THEREOF | Brystol-Myers Squibb Company (US) | 2009-04-22 | — | — | EP | disclosed |
| US-20090075995-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2009-03-19 | — | — | US | disclosed |
| US-20090075995-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2009-03-19 | — | — | US | disclosed |
| US-20090075995-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2009-03-19 | — | — | US | disclosed |
| WO-2008021926-A2 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AND/OR AP-1, AND/OR NF-KB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008021926-A2 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AND/OR AP-1, AND/OR NF-KB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140135322-A1 | NOVEL COMPOUNDS AND THEIR USE IN THERAPY | PRNP, TBCA, HSPA5 | CPS1 112/4885HPGD 4032/4885USP2 2608/4885 |
| US-20090075995-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | NFKB2, NFRKB, NFKB1 | CPS1 2892/4885HPGD 3452/4885USP2 2235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.